115 related articles for article (PubMed ID: 14559828)
1. E-selectin up-regulation allows for targeted drug delivery in prostate cancer.
Bhaskar V; Law DA; Ibsen E; Breinberg D; Cass KM; DuBridge RB; Evangelista F; Henshall SM; Hevezi P; Miller JC; Pong M; Powers R; Senter P; Stockett D; Sutherland RL; von Freeden-Jeffry U; Willhite D; Murray R; Afar DE; Ramakrishnan V
Cancer Res; 2003 Oct; 63(19):6387-94. PubMed ID: 14559828
[TBL] [Abstract][Full Text] [Related]
2. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
3. The pharmacologic basis for antibody-auristatin conjugate activity.
Alley SC; Zhang X; Okeley NM; Anderson M; Law CL; Senter PD; Benjamin DR
J Pharmacol Exp Ther; 2009 Sep; 330(3):932-8. PubMed ID: 19498104
[TBL] [Abstract][Full Text] [Related]
4. Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity.
Doronina SO; Mendelsohn BA; Bovee TD; Cerveny CG; Alley SC; Meyer DL; Oflazoglu E; Toki BE; Sanderson RJ; Zabinski RF; Wahl AF; Senter PD
Bioconjug Chem; 2006; 17(1):114-24. PubMed ID: 16417259
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells.
Tassone P; Gozzini A; Goldmacher V; Shammas MA; Whiteman KR; Carrasco DR; Li C; Allam CK; Venuta S; Anderson KC; Munshi NC
Cancer Res; 2004 Jul; 64(13):4629-36. PubMed ID: 15231675
[TBL] [Abstract][Full Text] [Related]
6. Monomethylated selenium inhibits growth of LNCaP human prostate cancer xenograft accompanied by a decrease in the expression of androgen receptor and prostate-specific antigen (PSA).
Lee SO; Yeon Chun J; Nadiminty N; Trump DL; Ip C; Dong Y; Gao AC
Prostate; 2006 Jul; 66(10):1070-5. PubMed ID: 16637076
[TBL] [Abstract][Full Text] [Related]
7. CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma.
Tse KF; Jeffers M; Pollack VA; McCabe DA; Shadish ML; Khramtsov NV; Hackett CS; Shenoy SG; Kuang B; Boldog FL; MacDougall JR; Rastelli L; Herrmann J; Gallo M; Gazit-Bornstein G; Senter PD; Meyer DL; Lichenstein HS; LaRochelle WJ
Clin Cancer Res; 2006 Feb; 12(4):1373-82. PubMed ID: 16489096
[TBL] [Abstract][Full Text] [Related]
8. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity.
Perera RM; Narita Y; Furnari FB; Gan HK; Murone C; Ahlkvist M; Luwor RB; Burgess AW; Stockert E; Jungbluth AA; Old LJ; Cavenee WK; Scott AM; Johns TG
Clin Cancer Res; 2005 Sep; 11(17):6390-9. PubMed ID: 16144944
[TBL] [Abstract][Full Text] [Related]
9. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
10. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors.
Goya M; Miyamoto S; Nagai K; Ohki Y; Nakamura K; Shitara K; Maeda H; Sangai T; Kodama K; Endoh Y; Ishii G; Hasebe T; Yonou H; Hatano T; Ogawa Y; Ochiai A
Cancer Res; 2004 Sep; 64(17):6252-8. PubMed ID: 15342412
[TBL] [Abstract][Full Text] [Related]
11. Targeting tomoregulin for radioimmunotherapy of prostate cancer.
Zhao XY; Schneider D; Biroc SL; Parry R; Alicke B; Toy P; Xuan JA; Sakamoto C; Wada K; Schulze M; Müller-Tiemann B; Parry G; Dinter H
Cancer Res; 2005 Apr; 65(7):2846-53. PubMed ID: 15805286
[TBL] [Abstract][Full Text] [Related]
12. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
Chari RV
Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
[TBL] [Abstract][Full Text] [Related]
13. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
14. A novel dietary triterpene Lupeol induces fas-mediated apoptotic death of androgen-sensitive prostate cancer cells and inhibits tumor growth in a xenograft model.
Saleem M; Kweon MH; Yun JM; Adhami VM; Khan N; Syed DN; Mukhtar H
Cancer Res; 2005 Dec; 65(23):11203-13. PubMed ID: 16322271
[TBL] [Abstract][Full Text] [Related]
15. Antitumor effects of thalidomide analogs in human prostate cancer xenografts implanted in immunodeficient mice.
Ng SS; MacPherson GR; Gütschow M; Eger K; Figg WD
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4192-7. PubMed ID: 15217957
[TBL] [Abstract][Full Text] [Related]
16. Development of potent monoclonal antibody auristatin conjugates for cancer therapy.
Doronina SO; Toki BE; Torgov MY; Mendelsohn BA; Cerveny CG; Chace DF; DeBlanc RL; Gearing RP; Bovee TD; Siegall CB; Francisco JA; Wahl AF; Meyer DL; Senter PD
Nat Biotechnol; 2003 Jul; 21(7):778-84. PubMed ID: 12778055
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human prostate cancer xenograft growth by 125I labeled triple-helix forming oligonucleotide directed against androgen receptor.
Zhang Y; Ma Y; Lu HP; Gao JH; Liang CS; Liu CZ; Zou JT; Wang HQ
Chin Med J (Engl); 2008 Nov; 121(22):2284-9. PubMed ID: 19080333
[TBL] [Abstract][Full Text] [Related]
18. In vitro and in vivo anticancer effects of the novel vitamin E ether analogue RRR-alpha-tocopheryloxybutyl sulfonic acid in prostate cancer.
Ni J; Mai T; Pang ST; Haque I; Huang K; DiMaggio MA; Xie S; James NS; Kasi D; Chemler SR; Yeh S
Clin Cancer Res; 2009 Feb; 15(3):898-906. PubMed ID: 19188160
[TBL] [Abstract][Full Text] [Related]
19. Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo.
Challita-Eid PM; Morrison K; Etessami S; An Z; Morrison KJ; Perez-Villar JJ; Raitano AB; Jia XC; Gudas JM; Kanner SB; Jakobovits A
Cancer Res; 2007 Jun; 67(12):5798-805. PubMed ID: 17575147
[TBL] [Abstract][Full Text] [Related]
20. Targeting epitopes in prostate-specific membrane antigen for antibody therapy of prostate cancer.
Kinoshita Y; Kuratsukuri K; Newman N; Rovito PM; Kaumaya PT; Wang CY; Haas GP
Prostate Cancer Prostatic Dis; 2005; 8(4):359-63. PubMed ID: 16172607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
